advertisement
Abstract #19129 Published in IGR 3-1
Additive ocular hypotensive effect of latanoprost 0.005% on previous beta antagonist-using patients
Machado Fontes ML; Ribeiro AL; Castor C; Yamane RRevista Brasileira de Oftalmologia 2000; 59: 711-717
OBJECTIVE: To evaluate the additive hypotensive effect of latanoprost 0.005% (Xalatan) on the eyes of hypertensive or glaucomatous patients with previous use of topic beta antagonists. PATIENTS AND METHODS: The study comprised 37 patients (68 eyes), already using beta antagonists for a period of not less than six months, and to which latanoprost 0.005% had been added. RESULTS: Prior to the association, mean intraocular pressure was 18.70 mmHg in both eyes. One month following the association, pressure went down to 15.01 mmHg and, after six months, to 14.43 mmHg, in both eyes. Intraocular pressure reduction after one month and six months of the association proved significant (p < 0.01). There was no significant variation in the values observed between one and six months of the association. CONCLUSIONS: Latanoprost 0.005% when administered once a day in patients suffering from ocular hypertension or chronic open-angle glaucoma, and who are users of beta antagonists, displays an additive effect in the reduction of intraocular pressure, which remains stable for six months. LA: Portuguese
Dr M.L. Machado Fontes, Rua Sorocaba, 138, Rio de Janeiro - RJ - CEP: 22271-110, Brazil
Classification:
11.4 Prostaglandins (Part of: 11 Medical treatment)